Medical University of Vienna at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Medical University of Vienna takes part in 13 sessions at ESMO 2026 in Madrid. Its program centres on cancer in the brain, from monitoring IDH-mutant glioma to drug treatment of brain metastases and spread to the brain's lining. Other sessions cover how tumours spread and shape their immune surroundings, adjuvant therapy in endometrial cancer, and managing metastatic breast cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Medical University of Vienna Vienna, Austria | |
Public medical university in Vienna, Austria, whose clinical departments are based at Vienna General Hospital. | Talk Fri Oct 23 13:30–13:50 How to select the optimal adjuvant therapy Gynaecological cancers Chair Fri Oct 23 13:30–15:00 Update on the mangement of endometrial cancer in the era of molecular classification Gynaecological cancers Abstract Fri Oct 23 13:35–13:40 696RO - Non-invasive finger sweat-based response monitoring of vorasidenib treatment in patients with IDH-mutant glioma Sarcoma, CNS, head & neck and rare cancers Abstract Fri Oct 23 14:37–14:42 703RO - Inflammatory and epigenetic signatures in progressive brain metastases after cranial radiotherapy Sarcoma, CNS, head & neck and rare cancers Keynote Fri Oct 23 15:15–15:20 Introduction Sarcoma, CNS, head & neck and rare cancers Chair Fri Oct 23 15:15–15:45 Keynote lecture 1 Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 08:50–09:10 Immune niche development and metastases Biomarkers & precision oncology Satellite Sat Oct 24 13:00–13:10 Overview GI Cancers: Translating Innovation into Practice and Better Patient Care Gastrointestinal cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:00–14:30 Servier - GI Oncology in Motion : Real-World Cases and Patient Centric Care Gastrointestinal cancersBiomarkers & precision oncology Chair Sun Oct 25 09:00–10:00 Abstract Sun Oct 25 09:42–09:52 Invited Discussant 3588O and 3592O Genitourinary cancers Abstract Sun Oct 25 10:15–10:25 690O - Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases (BMs) and leptomeningeal disease (LMD) Sarcoma, CNS, head & neck and rare cancers Chair Sun Oct 25 10:15–11:45 Proffered paper: CNS tumours Sarcoma, CNS, head & neck and rare cancers Chair Sun Oct 25 10:15–11:45 Chair Sun Oct 25 10:30–11:15 Chair Sun Oct 25 14:45–16:15 Chair Mon Oct 26 14:45–16:00 Modern management of leptomeningeal metastases Sarcoma, CNS, head & neck and rare cancers Chair Mon Oct 26 14:45–16:15 Talk Mon Oct 26 15:10–15:30 Systemic therapies for leptomenigeal disease Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 15:27–15:39 |
Instantly find 20 buyers from Medical University of Vienna
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction